Saccharopine dehydrogenase (NAD⁺, L-lysine-forming) (EC 1.5.1.7) catalyzes the oxidative deamination of N⁶-(L-1,3-dicarboxypropyl)-L-lysine (saccharopine) to L-lysine and 2-oxoglutarate, with NAD⁺ serving as a cofactor and H₂O as a reactant .
Lysine Biosynthesis: Converts saccharopine to lysine in the α-aminoadipic acid pathway .
Metabolic Regulation: Prevents toxic accumulation of saccharopine, which inhibits glucose-6-phosphate isomerase (GPI) and impairs neuronal development .
Antifungal Target: Unique to fungi, making it a candidate for antifungal drug development .
Mutations in the SDH domain of α-aminoadipic semialdehyde synthase (AASS) lead to hyperlysinemia-II, characterized by elevated cerebral saccharopine and lysine levels. This results in:
Impaired Neuronal Development: Saccharopine inhibits GPI’s neurotrophic effects, causing smaller brain size and developmental defects in mice .
Therapeutic Potential: Exogenous GPI supplementation rescues neuronal defects, highlighting saccharopine degradation as critical for brain development .
| Model | Mutation | Phenotype |
|---|---|---|
| AASS-G489E (SDH) | SDH domain defect | Elevated saccharopine, lysine; defective neurons |
| AASS-R65Q (LKR) | LKR domain defect | Elevated lysine; normal brain development |
In Neurospora crassa, CYS-3 (a transcription factor) upregulates sulfur-responsive genes, including transporters and enzymes for sulfur metabolism. While not directly linked to NCU03118, this underscores interconnected metabolic regulation in fungi .
Recombinant NCU07353 (saccharopine dehydrogenase) is commercially available for research:
| Parameter | Details |
|---|---|
| Source | Neurospora crassa |
| Purity | >85% (SDS-PAGE) |
| Applications | Western blotting, ELISA, enzymatic assays |
| Sequence | MVLPGHRLSPSGAKLQPRSLFKREANLDYRYAPEPCRAILTTCRVTSDCCSGMKCVSADGESVCTPSD |
Gene ID Discrepancy: No records for NCU03118 in UniProt, NCBI, or PubMed. Potential causes include:
Typographical error (e.g., NCU07353).
Strain-specific nomenclature not publicly documented.
Structural Gaps: Limited crystallographic data for fungal orthologs beyond PDB 1FF9 .
Therapeutic Potential: Further studies needed to explore antifungal targets or metabolic modulators .
This enzyme catalyzes the NAD+-dependent cleavage of saccharopine into L-lysine and 2-oxoglutarate, representing the final step in the α-aminoadipate (AAA) pathway for lysine biosynthesis.
KEGG: ncr:NCU03118